Increasing the decrement in insulin secretion improves glucagon responses to hypoglycemia in advanced type 2 diabetes

Diabetes Care

Volumn 28, Issue 11, 2005, Pages 2691-2696

  Israelian, Zarmen ^a   Gosmanov, Niyaz R ^b   Szoke, Ervin ^b   Schorr, Manju ^a   Bokhari, Syed ^a   Cryer, Philip E ^c   Gerich, John E ^b   Meyer, Christian ^a  

^a CARL T HAYDEN VA MEDICAL CENTER   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; C PEPTIDE; GLUCAGON; GLUCOSE; INSULIN; SODIUM CHLORIDE; TOLBUTAMIDE; ANTIDIABETIC AGENT;

ARTICLE; CONTROLLED STUDY; DRUG INFUSION; GLUCOSE BLOOD LEVEL; HORMONE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL; BLOOD; CHEMICALLY INDUCED DISORDER; GLUCOSE CLAMP TECHNIQUE; METABOLISM; PANCREAS ISLET; SECRETION;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; GLUCAGON; GLUCOSE CLAMP TECHNIQUE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; ISLETS OF LANGERHANS; TOLBUTAMIDE;

EID: 33644684529     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/diacare.28.11.2691     Document Type: Article

References (25)

1. Gerich J: Glucose counterregulation and its impact on diabetes mellitus. Diabetes 37:1608-1617, 1988
2. Samols E, Tyler J, Marks V: Glucagon-Insulin Interrelationships. New York, Pergamon, 1972
3. Hope KM, Tran PO, Zhou H, Oseid E, Leroy E, Robertson RP, Yang S, Zhang T: Regulation of α-cell function by the β-cell in isolated human and rat islets deprived of glucose: the "switch-off" hypothesis. Diabetes 53:1488-1495, 2004
4. Zhou H, Tran PO, Yang S, Zhang T, LeRoy E, Oseid E, Robertson RP: Regulation of α-cell function by the β-cell during hypoglycemia in Wistar rats: the "switch-off" hypothesis. Diabetes 53:1482-1487, 2004
5. Banarer S, McGregor VP, Cryer PE: Intraislet hyperinsulinemia prevents the glucagon response to hypoglycemia despite an intact autonomic response. Diabetes 51:958-965, 2002
6. Raju B, Cryer P: Loss of the decrement in intraislet insulin plausibly explains loss of the glucagon response to hypoglycemia in insulin deficient diabetes. Diabetes 54: 757-764, 2005
7. Gosmanov NR, Szoke E, Israelian Z, Smith T, Cryer PE, Gerich JE, Meyer C: Role of the decrement in intraislet insulin for the glucagon response to hypoglycemia in humans. Diabetes Care 28:1124-1131, 2005
8. Gerich J, Charles M, Grodsky G: Regulation of pancreatic insulin and glucagon secretion. Ann Rev Physiol 38:353-388, 1976
9. Gerich J, Lorenzi M, Bier D, Schneider V, Tsalikian E, Karam J, Forsham P: Prevention of human diabetic ketoacidosis by somatostatin: evidence for an essential role of glucagon. N Engl J Med 292:985-989, 1975
10. Abumrad N, Rabin D, Diamond M, Lacy W: Use of a heated superficial hand vein as an alternate site for the measurement of amino acid concentrations and for the study of glucose and alanine kinetics in man. Metabolism 30:936 -940, 1981
11. Shah S, Clutter W, Cryer P: External and internal standards in the single isotope derivative (radioenzymatic) assay of plasma norepinephrine and epinephrine in normal humans and persons with diabetes on chronic renal failure. J Lab Clin Med 106:624-629, 1985
12. Wallace TM, Levy JC, Matthews DR: Use and abuse of HOMA modeling. Diabetes Care 27:1487-1495, 2004
13. Hovorka R, Jones RH: How to measure insulin secretion. Diabetes Metab Rev 10: 91-117, 1994
14. Meyer C, Woerle HJ, Dostou JM, Welle S, Gerich JE: Abnormal postprandial renal, hepatic and muscle glucose metabolism in type 2 diabetes. Am J Physiol 287: E1049-E1056, 2004
15. Segel SA, Paramore DS, Cryer PE: Hypoglycemia-associated autonomic failure in advanced type 2 diabetes. Diabetes 51: 724-733, 2002
16. Hoy M, Olsen HL, Bokvist K, Buschard K, Barg S, Rorsman P, Gromada J: Tolbutamide stimulates exocytosis of glucagon by inhibition of a mitochondrial-like ATP-sensitive K (KATP) conductance in rat pancreatic A-cells. J Physiol 1:109-120, 2000
17. Bohannon NV, Lorenzi M, Grodsky GM, Karam JH: Stimulatory effects of tolbutamide infusion on plasma glucagon in insulin-dependent diabetic subjects. J Clin Endocrinol Metab 54:459-462, 1982
18. Ratzmann K, Schulz, Heinke P, Besche W: Tolbutamide does not alter insulin requirement in type I (insulin-dependent) diabetes. Diabetologia 27:8 -12, 1984
19. Peacey SR, Rostami-Hodjegan A, George E, Tucker GT, Heller SR: The use of tolbutamide-induced hypoglycemia to examine the intraislet role of insulin in mediating glucagon release in normal humans. J Clin Endocrinol Metab 82:1458-1461, 1997
20. Stumvoll M, Meyer C, Kreider M, Perriello G, Gerich J: Effects of glucagon on renal and hepatic glutamine gluconeogenesis in normal postabsorptive humans. Metabolism 47:1227-1232, 1998
21. Roden M, Perseghin G, Petersen KF, Hwang JH, Cline GW, Gerow K, Rothman DL, Shulman GI: The roles of insulin and glucagon in the regulation of hepatic glycogen synthesis and turnover in humans. J Clin Invest 97:642- 648, 1996
22. Taborsky GJ, Ahren B, Havel PJ: Autonomic mediation of glucagon secretion during hypoglycemia: implications for impaired α-cell responses in type 1 diabetes. Diabetes 47:995-1005, 1998
23. Brunicardi FC, Stagner J, Bonner-Weir S, Wayland H, Kleinman R, Livingston E, Guth P, Menger M, McCuskey R, Intaglietta M, Charles A, Ashley S, Cheung A, Ipp E, Gilman S, Howard T, Passaro E Jr: Microcirculation of the islets of Langerhans: Long Beach Veterans Administration Regional Medical Education Center Symposium. Diabetes 45:385-392, 1996
24. Franklin I, Gromada J, Gjinovci A, Theander S, Wollheim CB: β-Cell secretory products activate alpha-cell ATP-dependent potassium channels to inhibit glucagon release. Diabetes 54:1808-1815, 2005
25. Weyer C, Maggs DG, Young AA, Kolterman OG: Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control. Curr Pharm Des 7: 1353-1373, 2001